Call Buying Activity in Amarin Corp. (AMRN) Targets Upside in Shares Follow Q4 Earnings Beat -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amarin Corporation (AMRN) PT Lowered to $12 at Oppenheimer
February 26, 2020 7:13 AM ESTOppenheimer analyst Leland Gershell lowered the price target on Amarin Corporation (NASDAQ: AMRN) to $12.00 (from $13.00) while maintaining an Underperform rating.
The analyst commented, "Amarin's 4Q19 Vascepa sales of $142.0M (+85% year/year) brought FY19 total revenue to $429.8M, just above upper end of... More
Amarin Corporation (AMRN) Litigation Decision Expected in March, Possible Catalyst This Friday - Citi
February 26, 2020 6:29 AM ESTCiti analyst Joel Beatty reiterated a Buy rating and $24.00 price target on Amarin Corporation (NASDAQ: AMRN) ahead of the company's ANDA court decision next month which the analyst believes will be resolved positively. Post-trial briefs from are expected to be publicly available on... More
Amarin Corp. (AMRN) Tops Q4 EPS by 4c, Revs Beat; Reaffirms
February 25, 2020 4:12 PM ESTAmarin Corp. (NASDAQ: AMRN) reported Q4 EPS of $0.02, $0.04 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $143.3 million versus the consensus estimate of $136.01 million.
2019 was a transformational year for Amarin and for preventative cardiovascular patient care, commented John Thero, Amarins... More
